500万合同引发1.59亿元索赔 美迪西被客户质疑

Core Viewpoint - The lawsuit involving Medisi and Hongxu Biotechnology has raised significant concerns in the CRO industry due to the stark contrast between the original contract value of 5.58 million yuan and the claimed compensation amount of approximately 159 million yuan, highlighting contract risk issues within the industry [2][4]. Group 1: Lawsuit Details - Medisi's subsidiary, Medisi Puya, is being sued by Hongxu Biotechnology for a total of approximately 159 million yuan, despite the original contract being worth only 5.58 million yuan [2][4]. - The lawsuit stems from a technical service contract signed on December 18, 2020, where Medisi Puya was tasked with conducting non-clinical safety evaluations for a biopharmaceutical product [4]. - Hongxu Biotechnology claims that Medisi Puya breached the contract, leading to the request for contract termination and five specific claims totaling around 159 million yuan [5]. Group 2: Claims and Responses - The five claims made by Hongxu Biotechnology include: 1. Termination of the technical service contract 2. Payment of liquidated damages based on previously paid amounts 3. Refund of service fees already paid 4. Compensation for various losses totaling 1.5 billion yuan 5. Coverage of litigation and preservation costs [5]. - Medisi has firmly rejected Hongxu's claims, asserting that it has complied with industry standards and fulfilled its contractual obligations, as evidenced by the approval of the clinical trial on December 14, 2023 [7][8]. Group 3: Industry Context - The CRO industry is experiencing increased contract disputes as competition intensifies, with Medisi not being the only company facing such legal challenges [9]. - As the biopharmaceutical sector matures, the competition among CROs is shifting from scale and price to quality, service, and risk management capabilities, making risk control a critical focus for all CRO companies [9].